F-18 FDG PET/CT practice guideline in oncology: Assesment of treatment response F-18 FDG PET/BT onkolojik uygulama kılavuzu: Tedavi yanıtının belirlenmesi


ATASEVER T., Demirci E., SOYDAL Ç., Burak Z., UÇMAK G., BOZKURT M. F., ...Daha Fazla

Nuclear Medicine Seminars, cilt.6, sa.3, ss.358-369, 2021 (Scopus)

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 6 Sayı: 3
  • Basım Tarihi: 2021
  • Doi Numarası: 10.4274/nts.galenos.2020.0029
  • Dergi Adı: Nuclear Medicine Seminars
  • Derginin Tarandığı İndeksler: Scopus, EMBASE
  • Sayfa Sayıları: ss.358-369
  • Anahtar Kelimeler: FDG PET/CT, PERCIST, RECIST, Response assessment
  • Sağlık Bilimleri Üniversitesi Adresli: Evet

Özet

Assessing response to treatment is an important parameter in oncology practice and there is a growing body of evidence for use of F-18 fludeoxyglucose (FDG) positron emission tomography/computerized tomography (PET/CT) to evaluate response during or after the treatment. The use of FDG PET/ CT for this indication is increasing due to its advantages such as enabling rapid evaluation of all lesions and body parts in a single session, assessing viability in residual masses, not being limited to size measurements and low inter-observer variability. Many evaluation criteria have been proposed for standardization and interpretation of PET/CT findings. This guideline aims to provide a brief overview of proposed criteria and assist Nuclear Medicine Physicians in interpreting FDG PET/CT findings for the evaluation of the response.